Triadafilopoulos G.,Stanford University |
Taddei A.,University of Florence |
Bechi P.,University of Florence |
Freschi G.,University of Florence |
And 20 more authors.
Annals of the New York Academy of Sciences | Year: 2011
The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT 4 agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment. © 2011 New York Academy of Sciences. Source
Kallewaard J.W.,Rijnstate Hospital Velp |
Vanelderen P.,Ziekenhuis Oost Limburg |
Vanelderen P.,Radboud University Nijmegen |
Richardson J.,Royal Infirmary |
And 3 more authors.
Pain Practice | Year: 2014
Lumbosacral radicular pain is a pain in the distribution area of one of the nerves of the lumbosacral plexus, with or without sensory and/or motor impairment. A major source of lumbosacral radicular pain is failed back surgery, which is defined as persistent or recurrent pain, mainly in the region of the lower back and legs even after technically, anatomically successful spine surgeries. If lumbosacral radicular neuropathic pain fails to respond to conservative or interventional treatments, epiduroscopy can be performed as part of a multidisciplinary approach. Epiduroscopy aids in identifying painful structures in the epidural space, establishing a diagnosis and administering therapy. The novelty consists in the use of an epiduroscope to deliver therapies such as adhesiolysis and targeted administration of epidural medications. Clinical trials report favorable treatment outcomes in 30% to 50% of patients. Complications are rare and related to the rate or volume of epidural fluid infusion or inadvertent dural puncture. In patients with lumbosacral radicular pain, especially after back surgery, epiduroscopy with adhesiolysis may be considered (evidence rating 2 B+). © 2013 World Institute of Pain. Source
News Article | May 31, 2012
Today Leap Wireless, parent company to Cricket, announced that it has partnered with Apple to bring the iPhone to the U.S. prepaid market for the first time. Starting June 22nd, customers will be able to buy iPhone 4 and iPhone 4S models from Cricket on a prepaid wireless plan. The iPhones have been substantially subsidized by Cricket, indicating that the carrier is taking a financial hit to hop on the Apple bandwagon. Cricket offers an unlimited talk, text and data plan for only $55 (throttled after 2.3GB of usage), and customers can purchase the 8GB iPhone 4 for $400 off contract. The 16GB iPhone 4S is available for $500 off contract. These are the only two iPhone models Cricket will have available in June. “Our customers want the best products available and we are excited to bring iPhone to our pre-paid consumers with an industry leading $55 per-month service plan,” said Doug Hutcheson, president and chief executive officer, Leap Wireless International, Inc. “Launching iPhone is a major milestone for us and we are proud to offer iPhone customers attractive nationwide coverage, a robust 3G data network and a value-packed, no-contract plan.” Unlike AT&T, Verizon and Sprint, Cricket customers are not locked into a contract that prevents them from upgrading phones, switching around plans, or terminating subscriptions altogether. Carriers that offer 2-year contracts are able to offer smartphones for cheaper retail prices so customers can pay the full, unsubsidized cost over time. Apple offers unlocked, contract-free iPhones for about $150 more than Cricket ($650 for the 16Gb iPhone 4S), so the prepaid carrier is obviously paying out of pocket to offer its subscriber base a deal on the iPhone. Sprint took a similar financial gamble when it brought on the iPhone last October. This is the first time a major U.S. prepaid carrier has offered the iPhone, so it will be interesting to see how well sales go. Sprint owns Virgin Mobile and Boost Mobile, two other large prepaid networks, and we wouldn’t be surprised to see the iPhone make its way their as well. The iPhone will be available in Cricket stores and select dealers June 22nd in 60 U.S. markets. Customers can register on the Cricket website for more information. Update: Apple has officially commented on its partnership with Cricket:
Mirandola L.,TTUHSC |
Mirandola L.,Laura W Bush Institute For Womens Health |
Yu Y.,TTUHSC |
Cannon M.J.,University of Arkansas for Medical Sciences |
And 13 more authors.
Gynecologic Oncology | Year: 2014
Objective. Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3. Methods. We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancer patients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested. Result. We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients. Conclusions. Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer. © 2014 Elsevier Inc. All rights reserved. Source
Esser R.,University Hospital |
Muller T.,Chemotherapeutisches Forschungsinstitut Georg Speyer Haus |
Stefes D.,Chemotherapeutisches Forschungsinstitut Georg Speyer Haus |
Kloess S.,University Hospital |
And 12 more authors.
Journal of Cellular and Molecular Medicine | Year: 2012
Treatment of high-risk neuroblastoma (NB) represents a major challenge in paediatric oncology. Alternative therapeutic strategies include antibodies targeting the disialoganglioside GD 2, which is expressed at high levels on NB cells, and infusion of donor-derived natural killer (NK) cells. To combine specific antibody-mediated recognition of NB cells with the potent cytotoxic activity of NK cells, here we generated clonal derivatives of the clinically applicable human NK cell line NK-92 that stably express a GD 2-specific chimeric antigen receptor (CAR) comprising an anti-GD 2 ch14.18 single chain Fv antibody fusion protein with CD3-ζ chain as a signalling moiety. CAR expression by gene-modified NK cells facilitated effective recognition and elimination of established GD 2 expressing NB cells, which were resistant to parental NK-92. In the case of intrinsically NK-sensitive NB cell lines, we observed markedly increased cell killing activity of retargeted NK-92 cells. Enhanced cell killing was strictly dependent on specific recognition of the target antigen and could be blocked by GD 2-specific antibody or anti-idiotypic antibody occupying the CAR's cell recognition domain. Importantly, strongly enhanced cytotoxicity of the GD 2-specific NK cells was also found against primary NB cells and GD 2 expressing tumour cells of other origins, demonstrating the potential clinical utility of the retargeted effector cells. © 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd. Source